IM Cannabis (NASDAQ:IMCC – Get Free Report) and Trulieve Cannabis (NYSE:TRLV – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.
Valuation & Earnings
This table compares IM Cannabis and Trulieve Cannabis”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $39.17 million | 0.02 | -$8.10 million | ($60.66) | -0.01 |
| Trulieve Cannabis | $1.18 billion | 1.87 | -$116.38 million | $0.11 | 104.35 |
IM Cannabis has higher earnings, but lower revenue than Trulieve Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for IM Cannabis and Trulieve Cannabis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| Trulieve Cannabis | 1 | 1 | 1 | 0 | 2.00 |
Trulieve Cannabis has a consensus price target of $15.00, suggesting a potential upside of 30.67%. Given Trulieve Cannabis’ stronger consensus rating and higher probable upside, analysts plainly believe Trulieve Cannabis is more favorable than IM Cannabis.
Profitability
This table compares IM Cannabis and Trulieve Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | N/A | -58.32% |
| Trulieve Cannabis | -41.55% | -4.24% | -1.72% |
Insider and Institutional Ownership
7.7% of IM Cannabis shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Trulieve Cannabis beats IM Cannabis on 9 of the 13 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About Trulieve Cannabis
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
